FAP-1缺失损害巨核细胞分界膜系统与血小板功能并呈现骨髓纤维化样特征
本研究在FAP-1缺陷小鼠中发现早期巨核细胞增生伴血小板功能缺陷和偶发出血,老年小鼠出现骨髓纤维化样特征;机制上FAP-1缺失导致Src持续激活和cofilin失活,损害核周肌动蛋白重塑及DMS扩展;原发骨髓纤维化患者中FAP-1表达降低与DMS前巨核细胞积聚、DMS及肌动蛋白组织异常和Src激活相关。
要点
- FAP-1缺陷小鼠出现早期巨核细胞增生、血小板功能缺陷及偶发出血。
- FAP-1缺失通过Src持续激活和cofilin失活导致DMS前阻滞。
- 原发骨髓纤维化患者FAP-1低表达与DMS前巨核细胞积聚及Src激活相关。
核心结论
- FAP-1依赖的Src-cofilin介导的肌动蛋白重塑通路调控巨核细胞成熟和血小板功能,并可能是血小板功能障碍、出血并发症及纤维化相关疾病的治疗靶点。
研究设计与样本
- 研究使用FAP-1缺陷(FAP-1ΔP/ΔP)小鼠进行骨髓分析、骨髓移植和药理学抑制实验,并分析原发骨髓纤维化患者样本。
- 骨髓移植实验显示巨核细胞异常和纤维化相关改变是造血细胞内在的且部分可转移。
主要发现
- FAP-1缺陷小鼠出现早期巨核细胞增生、血小板功能缺陷和偶发出血,老年小鼠出现骨髓纤维化样特征。
- 骨髓分析显示巨核细胞DMS发育受损伴DMS前阻滞,导致前血小板形成缺陷、血小板功能受损和出血时间延长,部分与血块回缩减少相关。
- 机制上FAP-1缺失诱导Src持续激活和cofilin失活,损害DMS扩展所需的核周肌动蛋白重塑。
- 随着衰老,约一半小鼠出现症状性表型,包括髓外造血、肝脾肿大、贫血和血小板减少;其中多数保持纤维化前状态,一部分进展为纤维化样改变。
- 在原发骨髓纤维化患者中,FAP-1表达降低与DMS前巨核细胞积聚、DMS和肌动蛋白组织异常及Src激活相关。
临床怎么用
- FAP-1表达降低可能与原发骨髓纤维化患者的DMS前巨核细胞积聚和Src激活相关。
- 药理学抑制Src(达沙替尼)可减轻FAP-1缺陷小鼠的缺陷,支持通路特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fas-associated phosphatase 1 (FAP-1), a nonreceptor protein tyrosine phosphatase, has been implicated in multiple signaling pathways, but its in vivo role remains unclear. In this study, we showed that FAP-1-deficient (FAP-1ΔP/ΔP) mice develop early megakaryocyte (MK) hyperplasia with defective platelet function and occasional hemorrhagic manifestations, accompanied by myelofibrosis (MF)-like features, in aged animals. Bone marrow analyses revealed impaired demarcation membrane system (DMS) development with pre-DMS arrest in MK, which led to defective proplatelet formation, impaired platelet function, and prolonged bleeding that was partly associated with reduced clot retraction. Mechanistically, a FAP-1 deficiency induces sustained Src activation and cofilin inactivation, thereby impairing the perinuclear actin remodeling required for DMS expansion and leading to pre-DMS arrest. With aging, approximately half of the mice developed a symptomatic phenotype, characterized by extramedullary hematopoiesis, hepatosplenomegaly, anemia, and thrombocytopenia; among these, most remained in a prefibrotic state, whereas a subset progressed to fibrosis-like changes. A bone marrow transplantation demonstrated that the MK abnormalities and fibrosis-associated changes were hematopoietic cell-intrinsic and partially transferable. Pharmacologic inhibition of Src with dasatinib attenuated these defects in FAP-1-deficient mice, supporting pathway specificity. In patients with primary MF, reduced FAP-1 expression is associated with pre-DMS MK accumulation, abnormal DMS and actin organization, and Src activation, thus supporting clinical relevance. Collectively, we identified a FAP-1-dependent mechanism that governs the Src-cofilin-mediated actin remodeling required for MK maturation and platelet function and suggest this pathway as a potential therapeutic target for platelet dysfunction, hemorrhagic complications, and fibrosis-associated disease.
引用
- Chiu MF, Yeh KH, Chen PJ, et al. FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features. Blood. 2026. PMID: 42296014. doi:10.1182/blood.2025031490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。